Advertisement

Risk of liver retransplantation for viral hepatitis

  • Didier Samuel
  • Bruno Roche
  • Cyrille Feray
  • Henri Bismuth
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 29)

Abstract

The risk of viral recurrence after liver transplantation for viral related liver disease is high. Viral reinfection is characterized by a viral reactivation, high amount of virus, difficulty to control viral replication in these immunosuppressed patients, occurrence of graft disease, and sometimes graft failure. For these reasons, retransplantation for viral recurrence is controversial due to the high risk of recurrence on the second graft and to the overall poor results in a context of organ shortage.

Keywords

Graft Disease Adenine Arabinoside Vanish Bile Duct Syndrome Liver Retransplantation European Liver Transplant Registry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13: 619–626.PubMedGoogle Scholar
  2. 2.
    Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813–815.PubMedCrossRefGoogle Scholar
  3. 3.
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. and the investigators of the European concerted action on viral hepatitis study. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842–1847.PubMedCrossRefGoogle Scholar
  4. 4.
    Terrault NA, Combs Holland C, Ferrel L, Hahn JA, Lake JR, Roberts JP, Asher NL, Wright TL. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transplant. Surg. 1996; 2: 132–138.CrossRefGoogle Scholar
  5. 5.
    Marcellin P, Samuel D, Loriot MA, Areias J, Bismuth H, Benhamou JP. Anti-viral effect of adenine arabinoside monophosphate (ARA-AMP) in patients with recurrence of hepatitis B virus (HBV) infection after liver transplantation (abstract) Hepatology 1990; 12: 966.CrossRefGoogle Scholar
  6. 6.
    Gish RG, Lau JYN, Brooks L, Fang JWS, Steady SL, Imperial JC, Garcia-Kennedy R, Esquivel CO, Keefe EB. Ganciclovir treatment of hepatitis B virus (HBV) infection in liver transplant patients. Hepatology 1996; 23: 1–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kruger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, Böker KHW, Broelsch CF, Pichlmayr R, Manns MP. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplant. Surg. 1996; 2: 253–262.CrossRefGoogle Scholar
  8. 8.
    Perillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish R, Villeneuve J et al. Lamivudine for Hepatitis B after liver transplantation. Hepatology 1996; 24: 182A.CrossRefGoogle Scholar
  9. 9.
    Report of the European Transplant Registry, Hopital Paul-Brousse, Villejuif, France, 1994.Google Scholar
  10. 10.
    Wright TL, Donegan E, Hsu H, Ferrell L, Lake J, Kim M, Combs C, Fennessy S, Roberts J, Asher N. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317–322.PubMedGoogle Scholar
  11. 11.
    Feray C, Gigou M, Samuel D et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137–1143.PubMedGoogle Scholar
  12. 12.
    Gane E, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C virus infection after liver transplantation. N. Engl. J. Med. 1996; 334: 815–820.PubMedCrossRefGoogle Scholar
  13. 13.
    Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, Wilber J, Sheridan P, Urdea M. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773–779.PubMedCrossRefGoogle Scholar
  14. 14.
    Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N. Engl. J. Med. 1995; 330: 1160–1161 (letter).CrossRefGoogle Scholar
  15. 15.
    Feray C, Samuel D, Gigou M, Reynes M, Bismuth H. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995, 22: 1084–1089.PubMedCrossRefGoogle Scholar
  16. 16.
    Gane E, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant. Int. 1995; 8: 61–64.CrossRefGoogle Scholar
  17. 17.
    Bizollon T, Ducerf C, Trepo C. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin. J. Hepatol. 1995; 23(Suppl. 2): 22–25.PubMedGoogle Scholar
  18. 18.
    Sheiner PA, Schluger LK, Emre S, Thung SN, Lau JYN, Guy SR, Schwartz ME, Miller CM. Retransplantation for recurrent hepatitis C. Liver Transplant. Surg. 1997; 2: 130–136.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Didier Samuel
  • Bruno Roche
  • Cyrille Feray
  • Henri Bismuth

There are no affiliations available

Personalised recommendations